Key Highlights

  • Revenue was USD 4.4 billion, down 2%, non-GAAP EPS rose 10% to USD 0.86 and non-GAAP gross Margin was 58.7%.
  • AUSTEDO rose 21% to USD 751 million, AJOVY 61% to USD 269 million and UZEDY 96% to USD 85 million.
  • Free Cash Flow was USD 495 million, and GAAP net profit was USD 233 million.
  • Full-year Revenue guidance was raised to USD 16.7 billion to 17.0 billion, up USD 175 million at the midpoint.

Revenue, Margins and Earnings

Teva Pharmaceutical Industries (NYSE:TEVA) reported third-quarter 2026 revenue of USD 4.4 billion, down 2% in U.S. dollars and in local currency from the third quarter of 2025. The chief financial officer attributed the decline largely to lower generic products revenue, mainly generic REVLIMID, which was largely offset by growth in AUSTEDO, AJOVY and UZEDY. Chief Executive Officer Richard Francis said innovative revenue was up 32% and generics were down 16%.

Non-GAAP gross margin was 58.7%, reflecting a favorable mix of products. The CEO said EBITDA grew 7% and non-GAAP EPS was up 10%, at USD 0.86. GAAP net profit was USD 233 million, or USD 0.20 per share.

Free cash flow was USD 495 million, slightly below the prior year. In October 2026, the company repaid USD 1.8 billion of Debt maturities, and no amounts are outstanding under its revolving Credit facility. In the quarter it refinanced USD 4.9 billion of senior notes, and an S&P upgrade means it has investment-grade status with all three major rating agencies.

Analyst estimates were EPS of USD 0.72 against reported EPS of USD 0.86, and revenue of USD 4.25 billion against reported revenue of USD 4.40 billion.

Products and Pipeline

AUSTEDO revenue rose 21% globally to USD 751 million, with U.S. revenue of USD 727 million, up 21%, and the company reached its USD 2.5 billion target one year ahead of schedule. AJOVY revenue was USD 269 million, and UZEDY revenue was USD 85 million. The company is preparing for a fourth-quarter launch of WELTRUZA, a once-monthly olanzapine injectable, and expects no major revenue contribution in the fourth quarter because initial Volume is largely samples or vouchers.

The independent data monitoring committee conducted a pre-specified interim futility analysis of emrusolmin, and the company discontinued the Phase II study, with no safety concerns. The company completed the Acquisition of BXCL501 from BioXcel for a USD 57.5 million upfront payment and up to USD 67.5 million in contingent payments. It has 15 biosimilar products on the market and 16 in its pipeline.

Full-Year 2026 Guidance

The company raised full-year revenue guidance to USD 16.7 billion to USD 17.0 billion. It raised AUSTEDO to USD 2.55 billion to USD 2.65 billion, AJOVY to USD 930 million to USD 960 million and UZEDY to USD 290 million to USD 310 million. Operating Income is guided at USD 3.8 billion to USD 3.9 billion, or a margin of 22.6% to 23.1%, and 27.8% to 28.2% excluding in-process research and development. Adjusted EBITDA is guided at USD 4.23 billion to USD 4.43 billion, diluted EPS at USD 1.92 to USD 2.11 and free cash flow at USD 2.1 billion to USD 2.4 billion.

The company continues to guide non-GAAP gross margin at 54.5% to 55.5% and a tax rate of 20% to 23%. It targets an Operating Margin of 30% by 2027 and net debt to EBITDA of 2 times by the end of 2027.

Items to Follow

Items to follow are the WELTRUZA launch, AUSTEDO revenue in the fourth quarter ahead of the January IRA implementation, generic REVLIMID revenue and progress toward the 2027 operating margin target.